You just read:

EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD)

News provided by

EIP Pharma LLC

Jun 03, 2015, 08:00 ET